RxDoctor Payments Data

Carlos Perez Lopez, MD

Infectious Disease · San Juan, PRNPI 1861810012

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Johnson & Johnson at 28.4% of the total. 2025 is the largest year on record at $323, 3.8 times the $86 reported in 2020.

$1,294in general payments, 2019–2025

Across 51 payments — averaging $25.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$368
  • AbbVie$258
  • Johnson And Johnson International$123
  • Stryker$106
  • AstraZeneca$100
  • Amgen$99
  • plus $241 from 7 others

What the payments were for

  • Food & beverage$1,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson17$368
AbbVie11$258
Johnson And Johnson International2$123
Stryker1$106
AstraZeneca(2 entities)4$100
Amgen5$99
Genentech USA, Inc.3$80
Adaptive Biotechnologies Corporation2$42
Rigel Pharmaceuticals, Inc.2$34
Sanofi-aventis U.S. LLC1$27
Eli Lilly Export S.A. Puerto Rico Branch1$25
Kadmon Pharmaceuticals LLC1$17
Jazz Pharmaceuticals Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,294 in reported general payments places this provider in the 65th percentile of 127 infectious disease providers in Puerto Rico.

See all infectious disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,825
Medicare patients
15
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Acyclovir161$5,448
M-M-R Ii VaccineMeasles,mumps,rubella Vacc/Pf12$1,325
ValacyclovirValacyclovir Hcl15$1,190
Engerix-B AdultHepatitis B Virus Vaccine/Pf11$892
IpolPoliomyelitis Vaccine, Killed15$851
Levofloxacin11$91
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$74

Paid to pharmacies, not to this prescriber.

Other infectious disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →